Compare AbCellera Biologics Inc (ABCL) vs Wolfspeed Inc (WOLF) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Wolfspeed (WOLF) trades at $39.47, down 1.33% today, amid bearish technical signals and negative profitability metrics. The company shows strategic progress with AI data center revenue growth and key partnerships, though it faces significant financial challenges with negative gross margins and net losses. Technical indicators show the stock testing support levels with overall bearish momentum despite some neutral oscillators.

The outlook remains cautious with Wall Street divided (31.58% buy ratings) amid ongoing losses and competitive pressures. Near-term catalysts include the Q2 2026 earnings report and execution on defense/aerospace partnerships, but investors face substantial risk from cash burn and market volatility in the semiconductor sector.